Trial Profile
A phase II study of MabCampath [alemtuzumab] combined with fludarabine in patients with refractory B-cell chronic lymphocytic leukaemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2005
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 04 Aug 2005 New trial record.